Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer

EGFR exon 20 insertion (20ins)-positive non-small-cell lung cancer (NSCLC) is an uncommon disease with limited therapeutic options and dismal prognosis. Here we report the activity, tolerability, potential mechanisms of response and resistance for dual targeting EGFR 20ins with JMT101 (anti-EGFR mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Shen, Zhuang, Wu, Han, Baohui, Song, Zhengbo, Guo, Wei, Luo, Feng, Wu, Lin, Hu, Yi, Wang, Huijuan, Dong, Xiaorong, Jiang, Da, Wang, Mingxia, Miao, Liyun, Wang, Qian, Zhang, Junping, Fu, Zhenming, Huang, Yihua, Xu, Chunwei, Hu, Longyu, Li, Lei, Hu, Rong, Yang, Yang, Li, Mengke, Yang, Xiugao, Zhang, Li, Huang, Yan, Fang, Wenfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261012/
https://www.ncbi.nlm.nih.gov/pubmed/37308490
http://dx.doi.org/10.1038/s41467-023-39139-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261012/
https://www.ncbi.nlm.nih.gov/pubmed/37308490
http://dx.doi.org/10.1038/s41467-023-39139-4

Ejemplares similares